Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval

This study aims to determine whether cancer drugs granted accelerated approval from the US Food and Drug Administration ultimately demonstrate clinical

Related Keywords

Boston ,Massachusetts ,United States ,San Diego ,California ,American ,Aarons Kesselheim , ,Commonwealth Fund ,American Association For Cancer Research Annual Meeting ,Division Of Pharmacoepidemiology ,National Clinical Trial ,Leukemia Lymphoma Society ,Microsoft ,Drug Administration ,European Organisation For Research ,Section Ref ,Key Regulatory ,Data Extraction ,Approval Determinations ,Quality Of Life Data ,Google Scholar ,European Organisation ,Cancer Core Quality ,Regulatory Outcome ,Regular Approval ,Microsoft Excel ,Year Outcomes ,Accelerated Approval ,Drs Liu ,Interest Disclosures ,Lymphoma Society ,Federal Trade Commission ,Arnold Ventures ,American Association ,Cancer Research Annual Meeting ,